Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS AnGes’ HGF Therapy Could Debut Before Year-End to Become 1st Gene Therapy in Japan; 2 More Products Anticipated in 2019
August 7, 2018
-
BUSINESS Opdivo Defended Crown with Ono’s Asia Sales Added, but Keytruda Triumph Would Come Soon
August 6, 2018
-
COMMENTARY There’s Room for Growth in Biosimilar Space, but Who Will Grab It?
August 3, 2018
-
BUSINESS AstraZeneca’s AI Translation System Could Bring Huge Impact If Materialized: Japan R&D Chief
August 2, 2018
-
BUSINESS Daiichi Sankyo Offloading 41 Off-Patent Drugs to Alfresa as It Sharpens Focus on Oncology
August 1, 2018
-
BUSINESS AI in Pharma - 2: Daiichi Sankyo Looks to Set Competitors Apart with Efficient Call Center
August 1, 2018
-
REGULATORY Inappropriate Drug Promotion at Clinics Involves Encouragement of Off-Label Use in Most Cases: Study
July 31, 2018
-
BUSINESS AI in Pharma - 1: Companies Going Digital in Sales Support but Still Embrace Rep Experience
July 30, 2018
-
BUSINESS Chugai Sees Solid Uptake for Tecentriq, Hemlibra but CEO Frets Pricing Stability
July 27, 2018
-
BUSINESS (Update) Eisai/Biogen Alzheimer’s Drug BAN2401 Slows Cognitive Decline by 30%
July 26, 2018
-
REGULATORY AMED Launches Study on Evaluating the Quality and Safety of Nucleic Acid Medicines to Promote Their Development
July 25, 2018
-
ACADEMIA Debut of siRNA Therapeutic Looming on Horizon; Alnylam’s Patisiran Might Be Filed in Japan Too
July 24, 2018
-
BUSINESS Daiichi Sankyo’s Herceptin Biosimilar Might Hit Market as Early as November, Breast Cancer Use Also Eyed
July 23, 2018
-
BUSINESS Maruho to Increase Information Supply to Non-Dermatologists Using Digital Technology
July 23, 2018
-
BUSINESS Steep Hikes in Prices of Chinese-Made APIs Could Hit Generic Makers Hard
July 20, 2018
-
REGULATORY Lawmakers Question Rationale for PMD Law Amendment as LDP Launches Debate
July 19, 2018
-
ACADEMIA Japanese Society of Medical Oncology to Update I/O Guidelines in October
July 18, 2018
-
BUSINESS Takeda Jettisons Japan Rights to Obesity Drug OBLEAN after Long Listing Limbo
July 17, 2018
-
TRENDS As Biosimilars Show Mixed Performances, Lantus Follow-On Is on a Roll
July 13, 2018
-
BUSINESS Otsuka Ventures into Antibody Space with Visterra Buyout
July 12, 2018
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…